- Bupa Platinum consultant
- Fee assured
- Awaiting verification
- Open Referral network
Offers
- Face-to-face consultations
- Video and telephone consultations
About me
Dr Yong Du completed his nuclear medicine specialist training at the Institute of Nuclear Medicine, University College Hospital in London. He was awarded a PhD in Cancer Sciences at University of Southampton for his work on lymphoma. He was the first recipient of the national HEFCE Clinical Senior Lectureship Award in the Nuclear Medicine specialty (awarded in June 2009). He holds the Consultant in Nuclear Medicine and PET/CT Imaging position at The Royal Marsden Hospital.
In conjunction with his clinical practice, he has research interests to further assess the role, efficacy and limitations of PET/CT in various cancers, so as to optimise its use and inform tailored treatments for individual patients. Dr Yong Du also has extensive experience in radionuclide targeted therapy. He is interested in combining the fast advancing functional imaging technology with multidisciplinary expertise to help develop and optimise radionuclide targeted therapy for cancer patients. In collaboration with researchers across the country, Dr Yong Du has led and contributed to a number of international and national studies, has published first-authored research papers in high-impact oncology journals including Journal of Clinical Oncology, Blood, Cancer Research, EJNMMI, etc.
Dr Yong Du is a Trustee of the British Nuclear Medicine Society. He also serves at a number of international and national medical committees including the French AERES committee, the NCRI PET Research Network, the BNMS Radionuclide Targeted Therapy Committee, the NCRI Clinical and Translational Radiotherapy (CTRad) Research Working Group.
Areas of interest
Diagnostic Nuclear Medicine, PET/CT, SPECT/CT; Radionuclide Targeted Therapy for Neuroendocrine Tumour, Prostate Cancer (Dr Yong Du was awarded the first clinical ARSAC licence in UK to treat prostate cancer with Lu-177-PSMA in February 2018), Bone Metastases (Clinical Lead for National Xofigo [Radium-223] Therapy Training Programme), Lymphoma, Thyrotoxicosis, Thyroid Cancer, Polycythaemia Vera, Essential Thrombocythemia.
Medical secretaries
- Ms Sue Dixon
- Genesiscare UK 69 Alma Road Windsor SL4 3HD
- 01753 418444
- 01753 864036
- susan.dixon@genesiscare.co.uk
Information for healthcare professionals (Bupa patients only, last 12 months)
-
20365
Follow-up out-patient consultation - remote - (>50)
-
20355
Initial out-patient consultation - remote - (5-50)